Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Slate Path Capital LP Insider Profile
4 Followers
Slate Path Capital LP, Ten Percent Owner at Cyclerion Therapeutics, holds 0.00 shares in Cyclerion Therapeutics (Ticker: CYCN). Most recently, Slate Path Capital LP Sold $357,880 shares of Cyclerion Therapeutics on Nov 25, 2024 for an estimated value of 554.71K.
Slate Path Capital LP Cyclerion Therapeutics (CYCN)Ten Percent Owner
Cyclerion Therapeutics (CYCN)
Ten Percent Owner
Ranked #94,000 out of 99,797 Corporate Insiders
Profitable Transactions
0 out of 2 Profitable Transactions
Average Return
-113.40%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Slate Path Capital LP does not currently own shares as a corporate insider.
A breakdown of Slate Path Capital LP's holdings
Insider Roles
Ten Percent Owner
Roles that Slate Path Capital LP holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jun 07, 2021 - Jun 07, 2022
Return:-78.60%
The most profitable trade made by Slate Path Capital LP
Slate Path Capital LP's Trading History
List of latest transactions for each holding click on a transaction to see Slate Path Capital LP's performance on stock
You May Also Like
Slate Path Capital LP insider profile FAQ
What is the percentage of profitable transactions made by Slate Path Capital LP?
The percentage of profitable transactions made by Slate Path Capital LP is 0%.
What is the average return per transaction made by Slate Path Capital LP?
The average return per transaction made by Slate Path Capital LP is -113.40%.
What stocks does Slate Path Capital LP hold?
Slate Path Capital LP holds: CYCN stocks.
What was Slate Path Capital LP’s latest transaction?
Slate Path Capital LP latest transaction was an Informative Sell of $554.71K.
What was Slate Path Capital LP's most profitable transaction?
Slate Path Capital LP’s most profitable transaction was an Informative Buy of CYCN stock on June 7, 2021. The return on the trade was -78.60%.
What is Slate Path Capital LP's role in Cyclerion Therapeutics?
Slate Path Capital LP's role in Cyclerion Therapeutics is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.